High prescribing of short-acting reliever inhalers 'suggests asthma guidance not being followed'

Frequent prescribing of short-acting ß2 agonists (SABA) is widespread even in mild asthma, a new UK study shows, despite global guidance no longer recommending these medications alone for symptom relief.

by Chloe Harman
High use of short-acting beta2 agonists is associated with increased exacerbations and healthcare utilisation. | GETTY IMAGES
High use of short-acting beta2 agonists is associated with increased exacerbations and healthcare utilisation. | GETTY IMAGES

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package